- Home
- WVE vs PTGX Comparison
WVE vs PTGX Comparison
Compare WVE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- PTGX
- Stock Information
- Founded
- WVE 2012
- PTGX 2006
- Country
- WVE Singapore
- PTGX United States
- Employees
- WVE N/A
- PTGX N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- WVE Health Care
- PTGX Health Care
- Exchange
- WVE Nasdaq
- PTGX Nasdaq
- Market Cap
- WVE 2.4B
- PTGX 2.8B
- IPO Year
- WVE 2015
- PTGX 2016
- Fundamental
- Price
- WVE $13.67
- PTGX $41.11
- Analyst Decision
- WVE Strong Buy
- PTGX Strong Buy
- Analyst Count
- WVE 10
- PTGX 7
- Target Price
- WVE $21.30
- PTGX $53.57
- AVG Volume (30 Days)
- WVE 1.4M
- PTGX 529.7K
- Earning Date
- WVE 11-12-2024
- PTGX 11-07-2024
- Dividend Yield
- WVE N/A
- PTGX N/A
- EPS Growth
- WVE N/A
- PTGX N/A
- EPS
- WVE N/A
- PTGX 2.68
- Revenue
- WVE $53,610,000.00
- PTGX $323,795,000.00
- Revenue This Year
- WVE N/A
- PTGX $396.93
- Revenue Next Year
- WVE N/A
- PTGX N/A
- P/E Ratio
- WVE N/A
- PTGX $15.32
- Revenue Growth
- WVE N/A
- PTGX 125.73
- 52 Week Low
- WVE $3.50
- PTGX $16.01
- 52 Week High
- WVE $16.74
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- WVE 50.96
- PTGX 31.67
- Support Level
- WVE $14.95
- PTGX $45.23
- Resistance Level
- WVE $16.71
- PTGX $48.86
- Average True Range (ATR)
- WVE 1.04
- PTGX 2.16
- MACD
- WVE -0.28
- PTGX -0.79
- Stochastic Oscillator
- WVE 14.72
- PTGX 17.99
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.